Brief: Proteomics International Laboratories Secures Exclusive Licence To Commercialise Oesophageal Cancer Biomarkers
21/06/2022 02:34
June 21 (Reuters) - Proteomics International Laboratories
Ltd PIQ.AX :
* SECURES EXCLUSIVE LICENCE TO COMMERCIALISE OESOPHAGEAL
CANCER
BIOMARKERS
Source text for Eikon: ID:nASXYryst
Further company coverage: PIQ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Proteomics International Laboratories
See all newsBrief: Proteomics International Laboratories Launches Share Purchase Plan To Raise Up To A$5 MLN
Australia's Proteomics slips to four-month low on discounted share sale plan
Brief: Proteomics International Laboratories Posts FY Loss Attributable A$8.6 Million
Brief: Proteomics International Laboratories Signs Agreement With Healius For Promarker Portfolio
Australia's Proteomics International soars on distribution deal with Healius